Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Status:
Terminated
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify at least one dose of BMS-986001 which is safe, well
tolerated, and efficacious when combined with Efavirenz (EFV) + Lamivudine (3TC) for
treatment-naive Human Immunodeficiency Virus 1 (HIV-1) infected subjects